miR802 inhibits the aggressive behaviors of nonsmall cell lung cancer cells by directly targeting FGFR1
Emerging reports have revealed that several microRNAs (miRNAs) are abnormally expressed in nonsmall cell lung cancer (NSCLC). miRNAs have been identified as oncogenes or tumor suppressors, and regulate various biological processes including oncogenesis and development. miR802 is dysregulated
in multiple types of human cancer, and exerts tumorsuppressive or promoting roles. However, the expression levels and functional roles of miR802 in NSCLC remain largely unknown. In the present study, miR802 expression was demonstrated to be decreased in NSCLC tissues and cell lines. A low
miR802 expression was significantly correlated with the tumor stage, lymph node metastasis and brain metastasis in NSCLC patients. Restoring miR802 expression inhibited NSCLC cell proliferation and colony formation, induced cell apoptosis, decreased cell migration and invasion in vitro,
and hindered in vivo tumor growth. Mechanistically, fibroblast growth factor receptor 1 (FGFR1) was confirmed as the target gene of miR802 in NSCLC cells. In addition, FGFR1 silencing mimicked the tumorsuppressing roles of miR802 upregulation in NSCLC cells. Furthermore, rescue experiments
revealed that FGFR1 reintroduction rescued the miR802induced inhibition of the malignant phenotypes in NSCLC cells. Notably, miR802 was able to deactivate the phosphoinositide 3kinase (PI3K)/AKT serine/threonine kinase (Akt)/mammalian target of rapamycin (mTOR) pathway in NSCLC cells
in vitro and in vivo. Overall, these results demonstrated that miR802 could downregulate FGFR1 expression, thereby deactivating the PI3K/Akt/mTOR pathway and inhibiting the malignant development of NSCLC. Thus, miR802 may be a therapeutic candidate for patients with NSCLC.
Document Type: Research Article
Affiliations: 1: Guangzhou Institute of Respiratory Disease, State Key Laboratory of Respiratory Disease, Department of Respiration, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, P.R. China 2: Department of Neurosurgery, The Fifth People’s Hospital of Shanghai, Fudan University, Shanghai, 200240, P.R. China
Publication date: 01 January 2019
- The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content